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Health Related Quality of Life following Surgical Attenuation of Congenital 1 
Portosystemic Shunts versus Healthy Controls 2 
 3 
Summary 4 
Objectives: To design a health-related quality of life questionnaire for dogs with 5 
congenital portosystemic shunts, use this in a cohort of dogs treated with suture 6 
attenuation and compare results with that from a healthy control cohort. 7 
Methods: Data were collected from the hospital records of dogs treated with suture 8 
ligation of an intrahepatic or extrahepatic congenital portosystemic shunt at two referral 9 
centres. Owners were asked to complete a questionnaire assessing their dog’s health-10 
related quality of life pre-operatively (retrospectively) and at the time of follow-up. 11 
Owners of control dogs also completed the questionnaire.  12 
Results: 128 dogs with congenital portosystemic shunts and 131 control dogs were 13 
recruited. Median follow-up time was 64 months (range 19.7-157.2). The median long-14 
term health-related quality of life score was excellent for both intrahepatic (94/100) and 15 
extrahepatic (96/100) shunt cases and similar to that of control dogs. The long-term 16 
median CPSS scores of both IHCPSS and EHCPSS dogs were significantly worse than the 17 
control group. 18 
Clinical significance: Suture attenuation of congenitial portosystemic shunts is 19 
associated with an excellent health-realted quality of life score at long-term follow-up.  20 
 21 
 22 
 23 
 24 
 25 
Introduction 26 
 27 
A congenital portosystemic shunt (CPSS) is an abnormal vascular communication that 28 
diverts blood away from the portal circulation into the systemic circulation.  The CPSS 29 
may be intrahepatic or extrahepatic and results in liver hypoplasia and functional hepatic 30 
insufficiency. Surgery to attenuate the shunting vessel, thus re-directing hepatic portal 31 
blood flow to the liver, is the preferred treatment (Greenhalgh et al. 2014). There are 32 
several surgical techniques used to achieve partial or complete attenuation of both 33 
intrahepatic and extrahepatic CPSS in dogs including suture attenuation, cellophane 34 
banding, ameroid constrictor and coil embolisation (White et al. 1998, Youmans & Hunt 35 
1998, Hunt & Hughes 1999, Hunt 2004, Kummeling et al. 2004, Mehl et al. 2007, Falls et 36 
al. 2013, Murphy et al. 2001, Winkler et al. 2003) but few studies compare techniques, 37 
resulting in a lack of evidence to recommend one treatment over another (Tivers et al. 38 
2012, 2017). 39 
 40 
Additionally, there is a limited number of studies reporting the medium- to long-term 41 
follow-up after surgical attenuation and those available have varied time frames of 42 
follow-up. The current available reports have examined various techniques and different 43 
clinical variables to assess the outcome and success; including liver function tests 44 
(ammonia, bile acids), imaging to detect persistent shunting (scintigraphy and 45 
ultrasound) and owner assessment (Smith et al. 1995, White et al. 1998, Hunt & Hughes 46 
1999, Hunt 2004, Kummeling et al. 2004, Frankel et al. 2006, Mehl et al. 2007, Falls et 47 
al. 2013, Greenhalgh et al. 2014, Weisse et al. 2014, Winkler et al. 2014). Most studies 48 
assessing biochemical parameters as an outcome measure do not show a return to 49 
normal reference values (Bristow et al. 2017, Hunt et al. 1999; Lawrence et al. 1992), 50 
although those assessing owner outcome do show an apparent return to a “normal” 51 
quality of life.  However, for this latter long-term outcome, most studies use a simple 52 
form of owner assessment based on the resolution of clinical signs and whether the dog 53 
receives on-going medical management (Smith et al. 1995, Mehl et al. 2007, Falls et al. 54 
2013, Weisse et al. 2014, Greenhalgh et al. 2014). Based on the current published 55 
literature there appears to be a discrepancy in objective measures of outcome 56 
(biochemical changes) versus subjective outcome (owner perceived improvement using a 57 
brief assessment). Quality of life is an increasingly important outcome measure in both 58 
human and veterinary medicine (Fayers et al. 1997, Mellanby et al. 2003, Freeman et al. 59 
2005, Wiseman-Orr et al. 2006, Budke et al. 2008, German et al. 2012) but it is a 60 
difficult entity to assess for several reasons. There is no standardised definition, with 61 
different studies assessing different aspects under the umbrella term of health-related 62 
quality of life (HRQoL) and an extra challenge in veterinary medicine, as for paediatric 63 
medicine, is the lack of self-report, meaning the assessment has to be made by a third 64 
party. Furthermore, assessment is particularly complicated in dogs with CPSS as it is a 65 
congenital condition, so affected dogs are unlikely to have ever been truly ‘normal’, 66 
making assessment of whether dogs have made a full recovery, or simply improved, 67 
challenging. It is therefore imperative to compare the results of any questionnaire 68 
involving CPSS dogs to a population of healthy dogs, so that an accurate, more global 69 
evaluation of outcome can be made. The use of a consistent and detailed owner outcome 70 
assessment tool, including consideration of quality of life in comparison to more detailed 71 
analysis of presence or absence of continued clinical signs, and comparing to a control 72 
population, would be invaluable as part of the long-term outcome measure in dogs with 73 
CPSS. 74 
 75 
This study therefore had three main aims:  76 
(i) To develop a questionnaire for use in dogs with CPSS that would assess 77 
owner-estimated quality of life as well as presence or absence of clinical signs;  78 
(ii) To compare this direct quality of life score with a score designed to assess 79 
clinical signs in more depth; 80 
(iii) To compare these results to a control population of healthy dogs to assess the 81 
quality of recovery of CPSS dogs following surgical attenuation.  82 
 83 
Materials and Methods 84 
 85 
Recruitment of cases 86 
 87 
Medical records were reviewed for all dogs that had undergone surgical attenuation of a 88 
single, extrahepatic (EHCPSS) or intrahepatic (IHCPSS) CPSS between January 2000-89 
December 2012 at two centres (XX= centre 1, YY= centre 2). Attempts were made to 90 
contact the owners of these dogs by telephone, email or regular mail. Dogs were 91 
included if they had a partial or complete suture attenuation, had a minimum of 18 92 
months follow-up post-operatively and were alive at the time of data collection.  93 
 94 
Dogs were treated with either complete or partial suture attenuation depending on 95 
subjective and objective assessments of intra-operative portal hypertension as previously 96 
described (Kummeling et al. 2004, Lee et al. 2006, Cariou et al. 2009). At Centre 1, a 97 
polypropylene (Prolene)a ligature (size 2-0 to 3-0), was used to attenuate the shunts (full 98 
attenuation where possible), and a second surgery to perform full attenuation was 99 
recommended for all dogs that tolerated a partial attenuation at the first surgery. At 100 
Centre 2, 2-0 polyethylene terephthalate (Ethibond)b was used for attenuation in all 101 
dogs. Second surgeries if a full attenuation had not been achieved were not 102 
recommended if dogs had a good clinical response to the first surgery. 103 
 104 
Data collected from the medical records included signalment, body condition score (BCS), 105 
surgery date(s), type of shunt (EHCPSS or IHCPSS), whether complete or partial shunt 106 
attenuation was performed, whether a second surgery was performed and, when known, 107 
the presence of on-going shunting in the form of persistent flow through the CPSS or the 108 
development of multiple acquired shunts (MAS).  109 
 110 
Owners of a control population of healthy dogs were invited to complete the HRQoL 111 
questionnaire.  Control dogs were selected of the same breed and approximate ages as 112 
the CPSS population. Control dogs were recruited by contacting individual UK Kennel club 113 
breed societies and telephoning owners to ask them to participate in the study, a small 114 
number were recruited via Centre 1’s intranet from pets owned by non-clinical staff.  115 
 116 
Questionnaire development 117 
 118 
The questionnaire was developed on the basis of previously published veterinary 119 
questionnaires (Reid et al. 2013, Levan et al. 2013). A ‘direct’ QOL question was asked  120 
using a 10cm visual analog scale (VAS) from “worst imaginable” to “best imaginable” 121 
both before surgery and at long term follow up (Appendix 2). This was measured and 122 
converted to give a QoL score out of 100.  123 
 124 
For assessment of clinical signs, questions were developed on the basis of widely 125 
accepted clinical signs associated with CPSS (Berent & Tobias 2012). For each clinical 126 
sign, the frequency was recorded on a categorical scale from ‘never’ to ‘daily’.  From 127 
these questions a CPSS score was developed, to assess frequency and severity of clinical 128 
signs; signs were divided into three classes according to severity, with class 1 answers 129 
multiplied by 3, class 2 by 2 and class 3 by 1. Classes were determined subjectively by 130 
the authors, based on expert opinion (see Table 1) and multiplication numbers were 131 
determined arbitrarily based on expert opinion and previous work in this field 132 
(unpublished data). Consequently, greater CPSS scores represented a more severely 133 
clinically affected dog, with the highest score achievable of 110 134 
 135 
There were two parts to the questionnaire with Part 1 (Appendix 1) assessing variables 136 
pre- operatively and Part 2 at long-term follow up post-operatively (Appendix 2). The 137 
questionnaires also questions regarding general behaviour and the dogs willingness to 138 
participate in ‘normal’ canine activities including play, interaction with owners and other 139 
dogs and exercise. These questions were measured on a VAS scale  from ‘Not at all 140 
willing’ through to ‘Could not be more willing’. In addition, a question on the dog’s 141 
activity level was asked on a VAS scale from ‘Not active at all’ through to ‘Could not be 142 
more active’.  To capture the effect of CPSS on growth, owners were asked to report if 143 
their dog was considered small or underweight for their breed and age, and whether their 144 
body condition had changed since they acquired them. For further questionnaire design 145 
see Addendum 1.  146 
 147 
The questionnaire was either filled out by the owner whilst attending a hospital follow-up 148 
appointment for a concurrent study at Centre 1 (Bristow et al. 2017), or mailed or 149 
emailed to the owners. 150 
 151 
Statistical analysis 152 
 153 
Statistical analysis was performed using IBM SPPS Statistics v21. Continuous data were 154 
assessed graphically for normality. Mean and standard deviation were reported for 155 
normally distributed data and median and 25th-75th percentiles were reported for non-156 
normally distributed data. IHCPSS and EHCPSS dogs were analysed separately. 157 
Differences between the EHCPSS and IHCPSS dogs at long-term follow-up versus the 158 
control group were compared using the Mann-Whitney U test. Significance was set at 159 
P<0.05. Statistical analysis was not performed using part 1 of the questionnaire (pre-160 
operative results), due to the extended owner recall time. 161 
 162 
 163 
Results 164 
 165 
Demographics 166 
 167 
One hundred and twenty-three dogs met the inclusion criteria at Centre 1 and 132 at 168 
Centre 2.  Of these, 76 owners (61.8%) returned the questionnaire at Centre 1 and 52 169 
(39%) at Centre 2; resulting in 128 study dogs. 108 dogs had an EHCPSS and 20 an 170 
IHCPSS.  Median follow up time was 64 months (range 19.7-157.2).  171 
The most commonly represented breed in the EHCPSS group was the Yorkshire terrier 172 
(n=14), followed by the miniature schnauzer (n=12), (Table 2). In the IHCPSS group, 173 
golden retrievers (n=6), followed by Labrador retrievers (n=3) were the most commonly 174 
represented (Table 3). The mean age at follow up for EHCPSS dogs was 84.9 months (± 175 
37.2) and 74.8 months for IHCPSS dogs (± 28.7).  176 
One hundred and thirty-one control dogs were recruited (including three dogs via Centre 177 
1’s intranet). In the control group, cross breeds were the most commonly represented 178 
(n=13), followed by bichon frise (n=9), (Table 4). The mean age of the control dogs was 179 
93.5 months (± 28.8).  180 
 181 
Surgical treatment 182 
Seventy-one of 108 dogs with an EHCPSS (65.7%) had a full attenuation (in one or two 183 
surgeries), with 35 dogs (32.4%) having a partial attenuation only (n=34 with 184 
polyethylene terephthalate (Ethibond), n=1 with polypropylene (Prolene)), and two dogs 185 
(2%) diagnosed with MAS; one following partial attenuation (detected at the second 186 
surgery), and the second following a full attenuation (both with polypropylene).  187 
Nine of 18 dogs with an IHCPSS (50%) had a complete attenuation (in one or two 188 
surgeries, all with polypropylene (Prolene)), with nine dogs (50%) having a partial 189 
attenuation (n=7 with polyethylene terephthalate (Ethibond), n=2 with polypropylene 190 
(Prolene)).  Two dogs (10%) developed MAS; one following partial attenuation (detected 191 
at the second surgery), and the second following a full attenuation (both with 192 
polypropylene (Prolene)).  193 
 194 
At Centre 1, three dogs with MAS were receiving medical management with all three on a 195 
low protein diet, one on lactulose and one receiving occasional antibiotics when the 196 
owner felt ‘he was not acting his usual self’. One dog that had been treated with a partial 197 
attenuation was receiving antibiotics, lactulose and a low protein diet and a second 198 
partially-attenuated CPSS dog was receiving a low protein diet. A final dog that had been 199 
treated by complete attenuation was also on a low protein diet but the owner had 200 
decided to continue this after surgery contrary to recommendations.  201 
At Centre 2 no dogs were receiving medical management, all lactulose was discontinued 202 
immediately after surgery and low protein diet was transitioned to a normal diet over 1 203 
post-operative week.  204 
 205 
Questionnaire Results 206 
Summaries of the results of the questionnaire for EHCPSS dogs, IHCPSS dogs and control 207 
dogs are presented in tables 5-7 and Appendix 4. 208 
 209 
QoL Score 210 
 211 
The long-term median QoL score of dogs with an IHCPSS was 94 (83-97.5), which was 212 
not significantly different from the control group at 93 (82-98) (P=0.782). The long-term 213 
median QoL score of EHCPSS dogs was significantly greater than the control group 214 
(p=0.015) at 96 (89-100) (Table 5).  There was an increase in QoL score in both EHCPSS 215 
and IHCPSS dogs from pre-operatively to long-term follow-up (Table 5). 216 
 217 
CPSS Score 218 
 219 
The long-term median CPSS score of the IHCPSS (9 (1-26)) and EHCPSS (3 (1-10)) dogs 220 
were significantly worse than that of the control group (1 (0-3)), with these differences 221 
being statistically siginficant (p=0.003 for IHCPSS and p<0.001 for EHCPSS). CPSS score 222 
was improved at long-term follow-up in dogs with IHCPSS and EHCPSS compared to pre-223 
operatively, with the median percentage improvement in CPSS score from pre-224 
operatively to long term follow up 72.4% for dogs with IHCPSS, and 90.5% for dogs with 225 
EHCPSS (Table 5).  226 
 227 
 228 
Discussion  229 
To our knowledge this is the first study to use a HRQoL questionnaire to assess long-term 230 
outcome of surgical treatment of CPSS in dogs and to compare these results to a control 231 
population.  232 
 233 
Design of a HRQoL questionnaire allowed us to compare an overall owner reported 234 
health-related outcome in the form of the CPSS score (severity and frequency of clinical 235 
signs) with a direct QoL score. Previous studies of dogs treated for CPSS have relied on a 236 
brief owner assessment and one of our aims was to try to develop a more accurate 237 
assessment tool that takes into account these two important domains. A need for this 238 
more thorough type of evaluation is highlighted in this study by owners reporting the 239 
direct QoL to be excellent at long term follow up, and comparable to a control population,   240 
despite  both EHCPSS and IHCPSS groups having significantly worse CPSS scores than 241 
control dogs at long-term follow up. Clearly, both the QoL and a CPSS score such as we 242 
designed in this study are both necessary to provide complementary information to allow 243 
a more accurate overall long-term assessment of owner-derived outcome.  244 
 245 
The persistence of a relatively high CPSS score at follow-up, and one statistically higher 246 
than a control population, despite an apparent clinical improvement (based on QoL 247 
measurement), is a novel finding as it suggests that although surgery for partial or 248 
complete attenuation is associated with an improvement in frequency and severity of 249 
clinical signs, the majority of dogs undergoing CPSS attenuation do not go back to what 250 
is considered “normal”, when compared to a healthy control population. This potentially 251 
means that some dogs are being undertreated. If dogs do indeed have persistent subtle 252 
clinical signs then individuals may benefit from further treatment. The finding of a lack of 253 
return to “normal” fits with studies assessing other methods of outcome, for example, 254 
serum bile acid concentrations have been shown to not reduce to within reference 255 
intervals in the long-term in the majority of dogs with a complete shunt attenuation 256 
(Bristow et al. 2017). It is suggested that some dogs have continued microvascular 257 
shunting following CPSS surgery due to concurrent microvascular dysplasia or primary 258 
portal vein hypoplasia (PPVH) (O'Leary et al. 2014). O’Leary et al. (2014) proposed a 259 
spectrum of disease in dogs with CPSS, which could explain why some of these dogs 260 
have not returned to the baseline of “normal” on other tests from previous studies, as 261 
well as clinically in our study. People with liver disease can suffer from minimal hepatic 262 
encephalopathy (MHE) (Groeneweg et al. 1998, Shawcross et al. 2007), so that affected 263 
individuals do not show obvious signs of hepatic encephalopathy (HE) but do have 264 
significant abnormalities in neurophysiological performance and on psychometric testing 265 
and this might also occur in dogs.  266 
 267 
Further potential causes to be considered are that not all dogs in this study underwent 268 
imaging or blood testing to assess if MAS, persistent shunting or other abnormalities 269 
were present, and 32% of the EHCPSS cases had a partial attenuation without follow-up 270 
to determine if they had progressed to a full attenutation. 93% of these cases were 271 
attenuated partially with polyethylene terephthalate and it is therefore probable that 272 
some of them had progressed to a full attenuation, as even with partial attenuation using 273 
polypropylene, 25% have been shown to spontaneously progress to a full attenuation 274 
(unpublished data). Nevertheless some of these 32% of cases could have persistent 275 
shunting, thereby accounting for some of the results seen. Equally, the approximate rate 276 
of persistent shunting due to MAS is relatively low for dogs treated with suture ligation 277 
(Hottinger 1995, White 1998, Tivers et al. 2017) and on balance, this population here 278 
reflects standard clinical practice in many hospitals, of a combination of partial and 279 
complete attenuation achieved, thereby providing useful information in a large population 280 
of surgically teated dogs at follow up.  281 
  282 
Despite the discrepancy in QoL score and CPSS score, encouragingly, our data does also 283 
support the suggestion that suture attenuation of a CPSS results in a clinical 284 
improvement, with an improved CPSS score for both EHCPSS and IHCPSS from pre-285 
operatively compared to long-term follow up - use of this questionnaire prospectively 286 
(i.e. before and after surgery), will be able to provide statistical analysis on this 287 
improvement in the future.  288 
 289 
It is important to consider the limitations of owner based questionnaires, including 290 
attention bias, meaning that owners notice and remember ‘abnormal’ episodes more 291 
regularly, which could account for some of the difference in CPSS score, recall bias is 292 
another potential limitation to owner based assessment and owners of affected dogs may 293 
be more generous in their assessment of QoL compared to owners of “normal” dogs, as 294 
they have seen such a dramatic improvement after receiving treatment – as evidenced 295 
by the statistically better QoL observed by owners of CPSS dogs. Despite these 296 
limitations, HRQoL is becoming increasingly recognised as a very important factor for 297 
outcome measurement, with the emerging view in human medicine that it is an essential 298 
assessment to consider when measuring treatment success (Garratt et al. 2002).  299 
 300 
Design of a CPSS score was novel and based on expert opinion as has been the basis of 301 
designing questionnaires in other studies (Reid et al. 2013, Freeman et al. 2013). 302 
Naturally there will be differing expert opinions as to the impact of different clinical signs 303 
on quality of life, but this questionnaire was designed as a starting point to begin more 304 
in-depth analysis of outcome of CPSS dogs after treatment, leading on to future 305 
improvement in this assessment as well as the ability to compare different techniques in 306 
the future. As discussed in the introduction, there is a lack of evidence to currently 307 
recommend one treatment over another ( Tivers et al. 2012, 2017), and we should be 308 
striving to improve the evidence, with the use of validated instruments for comparisons. 309 
One of the strengths of this study is the availability of long-term information in a large 310 
number of dogs, which is often time-consuming and difficult to collect but essential in 311 
order to evaluate outcome of a condition and an intervention properly. It is hoped that 312 
use of a consistent HRQoL questionnaire tool for CPSS dogs will make this important on-313 
going task more manageable, easier to compare between different institutions, with a 314 
further benefit that it does not require the dog to return for a visit, blood test, sedation 315 
or anaesthesia, or imaging investigations.  316 
 317 
 318 
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